Strengthened Leadership, Operational Results, Strategic Collaborations and Protection of Intellectual Property - Research Report on Hologic, Stryker, Life Technologies, Boston Scientific and ResMed

NEW YORK, July 24, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Hologic Inc. (NASDAQ: HOLX), Stryker Corp. (NYSE: SYK), Life Technologies Corporation (NASDAQ: LIFE), Boston Scientific Corporation (NYSE: BSX) and ResMed Inc. (NYSE: RMD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Hologic Inc. Research Report

On July 18, 2013, Hologic Inc. (Hologic) announced the appointment of Jack W. Cumming as President and Chief Executive Officer, effective immediately. Mr. Cumming commented, "I look forward to working closely with the Board and leadership team to refine the Company's strategy, enhance performance and position Hologic to capitalize on the many opportunities ahead. I am confident we will continue to maintain our leadership role within the industry by developing cutting edge, state-of-the-art products that address the future needs of our customers and improve the lives of women." As per the Company, Mr. Cumming joined Hologic in 2001 and served as Chief Executive Officer from 2001 to 2009. The Full Research Report on Hologic Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-22/HOLX]

Stryker Corp. Research Report

On July 18, 2013, Stryker Corp. (Stryker) reported its Q2 2013 financial results with net sales growth of 5% YoY to $2.2 billion. Adjusted diluted net earnings per share increased 2% YoY to $1.00, while diluted net earnings per share decreased 34.1% YoY to $0.56. "We delivered another solid quarter of operational results with balanced sales growth across all segments and geographies, as well as strong cash flow performance," said Kevin A. Lobo, President and Chief Executive Officer. "Our earnings per share was impacted by foreign exchange headwinds which we expect to continue throughout the year." The Company anticipates full year 2013 sales growth in the range of 5% to 6.5% in constant currency. The Full Research Report on Stryker Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-22/SYK]

Life Technologies Corporation Research Report

On July 16, 2013, Life Technologies Corp. (Life Technologies) announced its collaboration with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, for current and future companion diagnostics projects. According to Life Technologies, the collaboration will seek to combine the biomarkers identified by Merck's translational research with Life Technologies' proprietary platform technologies and to develop companion diagnostics concurrently with Merck's drug development programs. "Life Technologies' combination of platforms and capabilities are unique in the companion diagnostics space, particularly in oncology," said Ronnie Andrews, President, Genetic & Medical Sciences at Life Technologies. "By helping pharma target the right cancer patients in clinical trials, we believe that we have the potential to rapidly accelerate cancer drug development and this is good for everyone - for Life Technologies and our pharma partners, and most importantly, for patients." The Full Research Report on Life Technologies Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-22/LIFE]

Boston Scientific Corporation Research Report

On July 19, 2013, Boston Scientific Corp. (Boston Scientific) launched a clinical trial to determine the safety and effectiveness of occipital nerve stimulation (ONS) using the Precision System in treating chronic migraine, when used in conjunction with anti-migraine medications. According to Boston Scientific, the OPTIMISE trial is expected to be used to support various regulatory approvals of this novel therapy for chronic migraine. "By directly targeting the occipital nerve with neurostimulation, we are potentially able to offer patients an effective and relatively low-risk therapy," said Richard Lipton, M.D., professor of neurology and director of the Montefiore Headache Center at Albert Einstein College of Medicine in New York and principal investigator for the study. "I am excited to further evaluate the clinical utility of the Boston Scientific Precision System with MICC technology as a treatment for chronic migraine." The Full Research Report on Boston Scientific Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-22/BSX]

ResMed Inc. Research Report

On July 18, 2013, ResMed Inc. (ResMed) announced that the U.S. government investigation started at the request of the Company against APEX Medical Corp., resulted in an administrative law judge at the International Trade Commission (ITC) determining that the ITC should enter a consent decree against APEX stopping the importation and sale of infringing APEX products. "We appreciate but are not surprised by the swift conclusion of this case against both APEX and Drive Medical Design," said ResMed global general counsel and chief administrative officer David Pendarvis. "This result is a testament to the strength of ResMed's intellectual property; our innovation is a significant market differentiator that puts comfortable and effective patient care first. We will continue to defend our patents and innovations against any future threats." The Full Research Report on ResMed Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-22/RMD]

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Investors' Reports